PAI
KPTI icon

Pittenger & Anderson Inc’s Karyopharm Therapeutics KPTI Stock Holding History

Pittenger & Anderson Inc’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$20 – 515
2025
Q3 		$20 Buy
+3
New +$16 ﹤0.01% 456

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Pittenger & Anderson Inc's KPTI Position: Q4 2025 in Review

Pittenger & Anderson Inc sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 3 shares — an estimated $20 sold.

Pittenger & Anderson Inc first reported a position in KPTI in Q3 2025 and held it in 1 quarter. The position peaked at $20 in Q3 2025. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Pittenger & Anderson Inc reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 3 Karyopharm Therapeutics shares in Q4 2025, an estimated $20.
  • Pittenger & Anderson Inc first reported a position in Karyopharm Therapeutics in Q3 2025 and held it in 1 quarter.
  • Pittenger & Anderson Inc's Karyopharm Therapeutics position peaked at $20 in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Pittenger & Anderson Inc's 13F filing for Q4 2025, filed 2 Feb 2026.